select count(*) as counts from cancer where `biomolecule` LIKE '%Protein%'

Browse Biomarkers Based on Biomolecules

This page shows data for Protein biomolecule.
Total Entries Retrieved: 766
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
1 p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA) Protein Humans Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666] Diagnostic Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate NA Tissue 12171882
2 p4036 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
3 p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
4 p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
5 p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
6 p4036+p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
7 p4036+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
8 p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
9 p4036+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
10 p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
11 p4639+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
12 p4036+p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
13 p4036+p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
18 Insulin Like Growth Factor-1 (IGF-1) Protein Mice Downregulated in SPI (soy protein isolate) diet: [Control: (223 ±61ng/ml; SPI Diet: 349 ±40 ng/ml ) Prognostic PCa Mice fed Control Diet Vs PCa Mice fed soy protein isolate Diet p<0.05 Serum 10460196
24 Caveolin-1 Protein Humans Upregulated in African American Men (AA: 39% vs WA: 17%) Prognostic African Americans vs White American men with Prostate Cancer p=0.0048 Tissue 10999725
25 Insulin Like Growth Factor-1 (IGF-1) Protein Humans Dowregulated (Preintervention: 232.7 ± 20.6 ng/mL Vs Postintervention: 16.92 ± 23.3 ng/mL) Predictive Prostate Cancer patients pre and post treatment with Lycopene p=0.0002 Plasma 11489752
26 Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Protein Humans Dowregulated (Preintervention: 5230 ± 244 ng/mL Vs Postintervention: 3924 ± 298 ng/mL) Predictive Prostate Cancer patients pre and post treatment with Lycopene p=0.0002 Plasma 11489752
27 BCL-2 Protein Humans Upregulated in High Gleason Score Prognostic High (8-10) vs Low (2-4) Gleason Score p<0.001 Tissue 11500787
28 Insulin Protein Humans Upregulated in High Risk Group Prognostic High vs (Medium and Low) Risk p= 0.05 Serum 11757030
31 Alpha Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in Localised Prostate Cancer [Mean expression Value: (Localised Prostate Cancer: 3.2 vs Normal Prostate: 1.3)] Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
32 Triiodothyronine Protein Humans Upregulated in Prostate Cancer (Control: 72 ±24.9; PCa: 83.9 ±18.1) Diagnostic Normal Prostate vs Localised Prostate Cancer p = 0.048 Serum 12441933
33 Triiodothyronine Protein Humans Upregulated in Prostate Cancer (PCa: 83.9 ±18.1 vs BPH: 94.4±12.3) Diagnostic Localised Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.013 Serum 12441933
34 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Moderate Risk Group p=0.041 Serum 12497024
35 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Low Risk Group p=0.013 Serum 12497024
36 Lycopene Protein Humans Downregulated (41% fold) Diagnostic Normal vs Cancerous p<0.05 Serum 12497123
37 Lycopene Protein Humans Downregulated (36% fold) Diagnostic Normal vs Cancerous p<0.05 Tissue 12497123
38 Annexin 1 Protein Humans Downregulated in Metastatic hormone refractory PCa (2.23 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
39 Annexin 2 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.51 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.009 Tissue 12507908
40 Annexin 4 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.3 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.001 Tissue 12507908
41 Annexin 7 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.42 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
42 Annexin 11 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.81 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
45 Fatty Acid Synthase (FAS) Intensity Protein Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000000857 Tissue 12939396
46 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 3.14 Vs Benign Prostate: 1.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.00001 Tissue 14982837
47 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 21.6 Vs Benign Prostate: 7.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.05 Tissue 14982837
48 phosphorylated Akt (pAkt) Protein Humans Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57) Prognostic PSA failure versus PSA non failure p<0.001 Tissue 15289328
49 phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) Protein Humans pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures Prognostic PSA failure versus PSA non failure NA Tissue 15289328
59 Kallikrein 4 (KLK4/hK4) Protein Humans Upregulated in PCa Diagnostic Benign prostatic hyperplasia Vs Prostate Cancer p<0.05 Tissue 16172196
60 BCL-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
61 COX-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
62 BCL-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
63 COX-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
64 Heat Shock Protein (Hsp70) Protein Mice Upregulated in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
65 Proliferating cell nuclear antigen (PCNA) Protein Mice Upregulated in PCa (1.44 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
66 Apoliprotein A-1 Protein Mice Upregulated in PCa (1.65 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
67 Phospholipase C Protein Mice Upregulated in PCa (1.95 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
68 Glucose regulated protein (GRP 58) Protein Mice Upregulatd in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
69 Enolase 1, Non-Neuron Protein Mice Upregulatd in PCa (1.8 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
94 E-cadherin Protein Humans Upregulated in Localised PCa (BPH: 7.26; Localised PCa: 9.46) Diagnostic Benign Prostatic Hyperplasia (BPH) Vs Localised PCa p=0.011 Serum 15870707
95 E-cadherin Protein Humans Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49) Prognostic Localised PCa Vs Metastatic PCa p<0.001 Serum 15870707
96 E-cadherin Protein Humans Iincreased risk of late biochemical failure with high expression Prognostic Biochemical Faliure Vs No Biochemical Faliure p<0.05 Serum 15870707
97 Thymosin b15 (Tb15) Protein Humans Upregulated in PCa Diagnostic Untreated Prostate Cancer Vs Controls p<0.001 Urine 15666387
98 Thymosin b15 (Tb15) Protein Humans Upregulated in PCa Diagnostic ADT treated Prostate Cancer Vs Controls p=0.001 Urine 15666387
99 Ghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
100 Preproghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
107 18 proteins with Mass (Da) M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031+ M5265 +M15878 + M16003 + M16068 Protein Humans Downregulated in PCa: [M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031Upregulated in PCa: [M5265 +M15878 + M16003 + M16068] Diagnostic Prostate Cancer Vs Controls p<0.01 Serum 16372118
108 FPA Protein Humans Downregulated (0.58 fold) Diagnostic Normal vs Prostate Cancer p=0.000108 Serum 16395409
109 Fibrogen alpha Protein Humans Downregulated (0.33 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000000763 Serum 16395409
110 inter-α-trypsin inhibitor heavy chain H4 (ITIH4) Protein Humans Upregulated (121 fold) Diagnostic Normal vs Prostate Cancer p=0.0000108 Serum 16395409
111 Clusterin Beta Protein Humans Upregulated (251 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000481 Serum 16395409
112 factor X111a Protein Humans Upregulated (2.84 fold) Diagnostic Normal vs Prostate Cancer p=0.0000000143 Serum 16395409
113 PCaP Polypeptide Panel (PCAPP) Protein Humans Differentially Expressed in Prostate Cancer Diagnostic Prostate Cancer Vs Healthy Controls p<0.05 Urine 19759844
117 ααCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
118 ββCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
119 NTx Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
120 ICTP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
121 BSAP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
122 TRAP5b Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
123 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
124 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p=0.0108 Tissue 16614113
125 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 4 Prognostic Gleason Pattern 3 Vs Gleason Pattern 4 p=0.042 Tissue 16614113
126 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 5 Prognostic Gleason Pattern 4 Vs Gleason Pattern 5 p=0.037 Tissue 16614113
127 Neuropeptide Y (NPY) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
128 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
129 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p<0.0001 Tissue 16614113
130 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
137 β-2-Microglobulin Protein Humans Upregulated in Metastatic Prostate Cancer (Controls: 1.9± 0.6; Metastatic Castrate PCa: 2.7 ± 1.1) Diagnostic Controls Vs Metastatic Castrate Prostate Cancer p<0.05 Serum 17404077
140 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.02 Tissue 15491717
141 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
142 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
143 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
144 H3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
145 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
146 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
147 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
148 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
149 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
150 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
151 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
152 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
153 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
154 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
155 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
156 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
157 Lipoxygenase Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
158 Caspase-3 Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
220 VEGF (Vascular Endothelial Growth Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
221 Resistin Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.04 Serum 17932343
222 IL-1Ra (Interleukin 1Ra) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.03 Serum 17932343
223 MMP-3 (Matrix Metalloproteinase-3) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
224 PAI-1(active) (Plasminogen Activator Inhibitor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
225 AFP (α- Fetoprotein) Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
226 Kallikrein-8 Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
227 PSA Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.0001 Serum 17932343
228 G-CSF (Granulocyte Colony-Stimulating Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.005 Serum 17932343
239 Anterior Gradient 2 Homolog AGR2 Protein Humans Upregulatated in PCa (3.8 fold) Diagnostic Normal Vs Prostate Cancer p=0.0021 Serum 18061988
240 YKL- 40 Protein Humans Upregulated in PCa (PPC: 188.01 Vs BPH: 73.54 ± 9.25) Diagnostic Benign Prostatic Hyperplasia vs Primary Prostate Cancer p<0.001 Serum 18190830
241 Chitotriosidase Protein Humans Upregulated in PCa (PCa: 91.33 ± 8.32 Vs BPH: 69.72 ±8.69) Diagnostic Normal (Control) Vs Cancer (High Gleason Grade) p<0.05 Serum 18190830
242 CXCL12 Protein Humans Upregulated in Biopsy Positive Patients Diagnostic Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer p=0.05 Serum 18196514
253 AMACR (Alpha-methylacyl-coA racemase ) Protein Humans Upregulated in PCa Diagnostic High Grade Prostatic Intraepithelial Neoplasia Vs Prostate Cancer p=0.0044 Tissue 18343427
254 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic Overall Survival Vs No Survival p<0.0001 Plasma 18428198
255 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic PSA Decline Vs No PSA decline p=0.0068 Plasma 18428198
281 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.01 Tissue 18543251
282 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate epithelium p<0.001 Tissue 18543251
284 %[-2]proPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.001 Serum 18550118
285 PSA+BPSA+%fPSA+%[-2] proPSA+[-2]proPSA/BPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p<0.05 Serum 18550118
286 %fPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.008 Serum 18550118
287 40S ribosomal protein S25 Protein Humans Upregulated (Mean Ratio: 2.13 ±0.44) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
288 40S ribosomal protein S7 Protein Humans Upregulated (Mean Ratio: 5.24 ±0.66) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
289 α-1-antitrypsin precursor (α-1protease inhibitor) Protein Humans Upregulated (Mean Ratio: 3.19 ±0.97) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
290 Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) Protein Humans Upregulated (Mean Ratio: 2.33 ±0.79) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
291 Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment) Protein Humans Upregulated (Mean Ratio: 2.28 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
292 Chromobox protein homologue 1 (Heterochromatin protein 1 homologue β) Protein Humans Upregulated (Mean Ratio: 3.36 ±0.50) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
293 Cofilin-1 (Cofilin, nonmuscle isoform) (18 kDa phosphoprotein) (p18) Protein Humans Upregulated (Mean Ratio: 3.29 ± 1.2) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
294 Complement component 1 Q subcomponent-binding protein (p33) Protein Humans Upregulated (Mean Ratio: 4.55 ± 1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
295 Elongation factor 1-R 2 (Elongation factor 1 A-2) (Statin S1) Protein Humans Upregulated (Mean Ratio: 2.68 ±0.73) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
296 Ezrin (p81) (Cytovillin) (Villin-2) Protein Humans Upregulated (Mean Ratio: 2.26 ±0.0.49) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
297 FASN variant protein (Fragment) Protein Humans Upregulated (Mean Ratio: 2.78 ±0.91) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
298 FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (Rotamase) Protein Humans Upregulated (Mean Ratio: 2.46 ±0.29) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
299 Glutamate carboxypeptidase 2 (Folate hydrolase 1) (Prostate- specific membrane antigen) Protein Humans Upregulated (Mean Ratio: 2.82 ±0.95) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
300 Glutathione peroxidase 3 precursor Protein Humans Upregulated (Mean Ratio: 2.19 ±0.57) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
301 Glutathione S-transferase ω-1 Protein Humans Upregulated (Mean Ratio: 2.36 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
302 Heat shock protein HSP90-β Protein Humans Upregulated (Mean Ratio: 3.2 ±0.61) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
303 Histone cluster 1, H1e Protein Humans Upregulated (Mean Ratio: 3.5 ±0.82) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
304 Histone H1.2 (Histone H1d) Protein Humans Upregulated (Mean Ratio: 2.98 ±1.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
305 Lactoylglutathione lyase (Aldoketomutase) (Glyoxalase I) Protein Humans Upregulated (Mean Ratio: 2.06 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
306 α-methylacyl-CoA racemase (AMAC) Protein Humans Upregulated (Mean Ratio: 2.51 ±0.62) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
307 Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) Protein Humans Upregulated (Mean Ratio: 2.6 ±1.01) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
308 Periostin, osteoblast specific factor Protein Humans Upregulated (Mean Ratio: 3.38 ± 1.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
309 Prostaglandin E synthase 3 (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone receptor complex p23) Protein Humans Upregulated (Mean Ratio: 3.14 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
310 Proteasome subunit alpha type 5 (Multicatalytic endopeptidase complex ?-chain) Protein Humans Upregulated (Mean Ratio: 2.07 ±1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
311 Protein mago nashi homologue 2 Protein Humans Upregulated (Mean Ratio: 2.18 ±0.43) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
312 Protein-glutamine γ-glutamyltransferase 4 (Prostate transglutaminase) (Prostate-specific transglutaminase) Protein Humans Upregulated (Mean Ratio: 3.45 ±1.00) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
313 Thioredoxin domain-containing protein 4 precursor Protein Humans Upregulated (Mean Ratio: 2.54 ±0.45) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
314 Ubiquinol-cytochrome c reductase complex 11 kDa protein Protein Humans Upregulated (Mean Ratio: 2.90 ±0.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
315 14-3-3 protein β/α Protein Humans Downregulated (Mean Ratio: 0.52 ±0.1) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
316 Androgen receptor-associated protein of 55 kDa (ARA 55) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
317 α-parvin (Calponin-like integrin-linked kinase-binding protein) (CH-ILKBP) Protein Humans Downregulated (Mean Ratio: 0.53 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
318 Angiotensin-converting enzyme, somatic isoform (precursor) (CD143 antigen) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
319 Ankyrin repeat domain-containing protein 25 (SRC-1-interacting protein) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
320 BCL2-associated athanogene 3 variant (Fragment) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
321 CD44 antigen precursor (Phagocytic glycoprotein I) (Hyaluronate receptor) (Epican) Protein Humans Downregulated (Mean Ratio: 0.23 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
322 Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen) Protein Humans Downregulated (Mean Ratio: 0.49 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
323 Ciliary dynein heavy chain 10 (Axonemal beta dynein heavy chain 10) (Fragment) Protein Humans Downregulated (Mean Ratio: 0.35 ±0.05) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
324 Collagen α-1(V) chain precursor Protein Humans Downregulated (Mean Ratio: 0.41 ±0.19) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
325 Collagen α-1(VI) chain precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.15) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
326 Flotillin-1 Protein Humans Downregulated (Mean Ratio: 0.33 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
327 G antigen family C member 1 (Prostate-associated gene 4 protein) Protein Humans Downregulated (Mean Ratio: 0.25 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
328 γ-synuclein (Persyn) (Breast cancer-specific gene 1 protein) (Synoretin) Protein Humans Downregulated (Mean Ratio: 0.18 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
329 Glutathione S-transferase μ-1 Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
330 Glutathione S-transferase π-1 Protein Humans Downregulated (Mean Ratio: 0.29 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
331 Hsc70-interacting protein (Hip) (Putative tumor suppressor ST13) (Progesterone receptor-associated p48 protein) Protein Humans Downregulated (Mean Ratio: 0.33 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
332 Insulin-degrading enzyme (Insulysin) (Insulinase) (Insulin protease) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
333 Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (Prostacyclin-stimulating factor) (PGI2-stimulating factor) Protein Humans Downregulated (Mean Ratio: 0.42 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
334 Kallikrein-11 precursor (Hippostasin) Protein Humans Downregulated (Mean Ratio: 0.41 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
335 Keratin, type I cytoskeletal 17 (Cytokeratin-17) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
336 Leiomodin-1 (64 kDa autoantigen 1D) Protein Humans Downregulated (Mean Ratio: 0.21 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
337 Microtubule-associated protein 1B (MAP 1B) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
338 Olfactomedin-like protein 1 precursor Protein Humans Downregulated (Mean Ratio: 0.33 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
339 Phosphoglucomutase-like protein 5 (Aciculin) Protein Humans Downregulated (Mean Ratio: 0.47 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
340 Platelet-activating factor acetylhydrolase IB subunit α Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
341 Prostatic acid phosphatase [Precursor] Protein Humans Downregulated (Mean Ratio: 0.42 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
342 Ras-related protein R-Ras (p23) Protein Humans Downregulated (Mean Ratio: 0.31 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
343 Retinol binding protein I, cellular Protein Humans Downregulated (Mean Ratio: 0.28 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
344 Selenium binding protein 1 (SELENBP1 protein) Protein Humans Downregulated (Mean Ratio: 0.36 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
345 TFIIH basal transcription factor complex helicase XPB subunit (DNA-repair protein complementing XP-B) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
346 Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Ubiquitin thioesterase L1 Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
347 Vinculin (Metavinculin) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
348 Zinc-α-2-glycoprotein precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
349 Zyxin Protein Humans Downregulated (Mean Ratio: 0.45 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
350 Transforming growth factor-β1 (TGF-β1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
351 soluble IL-6 receptor (sIL-6R) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
352 IL-6 Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
353 Vascular endothelial growth factor (VEGF) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p= 0.002; Multivariate: p=0.008 Plasma 18559597
354 Vascular cell adhesion molecule-1 (VCAM-1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
355 Endoglin Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001Multivariate: p=0.002 Plasma 18559597
356 Urokinase-type plasminogen activator (uPA) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
357 uPA receptor (uPAR) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001; Multivariate: p=0.05 Plasma 18559597
358 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA + PAI-1 + uPAR Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
359 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
360 IL-8 Protein Humans Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
361 Osteopontin Protein Humans Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
362 IL8 + Osteopontin Protein Humans Upregulated in Recurrent Group Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
365 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.009 Tissue 18767028
366 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.003 Tissue 18767028
367 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.006 Tissue 18767028
368 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.001 Tissue 18767028
369 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
370 PCNA Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
371 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.049 Tissue 18767028
372 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.028 Tissue 18767028
373 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.025 Tissue 18767028
374 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.027 Tissue 18767028
375 Her-2/neu Protein Humans Negative Staining in Patients with Progression Free Survival Prognostic Progression Free Survival Vs No Progression Survival p=0.001 Tissue 18767043
376 Her-2/neu Protein Humans Negative Staining in Patients with Metastatic Free Survival Prognostic Metastatic Vs Non Metastatic Prostate cancer p=0.002 Tissue 18767043
377 Her-2/neu Protein Humans Negative Staining in Patients with PCa Death Free Survival Prognostic PCa Specific Death Vs No PCa Specific Death p=0.021 Tissue 18767043
395 CCL4 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p=0.011 Tissue 19047106
396 CX3CL1 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p<0.0001 Tissue 19047106
397 CCL4 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 19047106
398 CX3CL1 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p<0.0001 Tissue 19047106
399 PSA+Surgical Margins+ seminal vesicle invasion+ Gleason Score+CX3CL1+CCL4+IL-15 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence NA Tissue 19047106
400 Ki-67 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
401 p53 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
402 BCL-2 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
403 Ki-67 Protein Humans Downregulated with Flaxseed supplemented Diet [ Control Diet: 3.23 (95% CI: 2.42-3.92), Flaxseed Supplementation: 1.66 (95% CI: 1.13-2.64)] Predictive Controls Vs Flaxseed Supplementation in Patients with PCa p=0.0013 Tissue 19064574
413 PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI Protein Humans Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI] Prognostic Recurrence Vs No recurrence for 5 years Training: p=0.012 Testing: p=0.011 Serum 19157448
417 Transforming growth factor-b1 Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.003 Plasma 19229851
418 Interleukin-6 soluble receptor ((IL-6sR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.001 Plasma 19229851
419 Interleukin-6 (IL-6) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001 Plasma 19229851
420 Vascular cell adhesion molecular 1 (VCAM 1) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
421 Vascular endothelial growth factor (VEGF) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p=0.002 Plasma 19229851
422 Endoglin Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
423 Urokinase-type plasminogen activator (uPA) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.036 Plasma 19229851
424 Urokinase-type plasminogen activator receptor (uPAR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
425 Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years NA Plasma 19229851
426 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.03; Tissue 19239456
427 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.001; Tissue 19239456
428 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p=0.01; Multivariate: p=0.01; Tissue 19239456
429 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p=0.001; Multivariate: p=0.004; Tissue 19239456
440 Ki-67 Protein Humans Differentially Expressed Prognostic Cause Specific Survival Vs No Survival p<0.001 Tissue 19293807
441 Ki-67 Protein Humans Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)] Prognostic Overall Survival Vs No Survival p<0.001 Tissue 19293807
454 MIC-1 (Macrophage inhibitory cytokine 1); A1BG a-1B-glycoprotein1 precursor; VTNC (Vitronectin precursor); RNPEP (Arginyl aminopeptidase); FETUA (Fetuin A) Protein Humans Upregulated in Docetaxel- resistant PC3-Rx cells [(MIC-1 Macrophage inhibitory cytokine 1 (2.4 fold); A1BG a-1B-glycoprotein1 precursor (1.9 fold) ; VTNC Vitronectin precursor (1.7 fold); RNPEP Arginyl aminopeptidase (1.6 fold); FETUA Fetuin A (1.6 fold)] Potential Predictive Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells p<0.05 Cell Lines 19773444
455 CYR61 (Angiogenic inducer 61); MASPIN (Serpin peptidase inhibitor); AGR2 (Anterior gradient 2 homologue); Protein Humans Downgregulated in Docetaxel- resistant PC3-Rx cells [(CYR61 Angiogenic inducer 61 (1.5 fold); MASPIN Serpin peptidase inhibitor (1.5 fold); AGR2 Anterior gradient 2 homologue (2.4 fold)]; Potential Predictive Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells p<0.05 Cell Lines 19773444
456 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy p=0.02 Blood 19773444
457 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy p=0.002 Blood 19773444
458 Prostate specific antigen (PSA), Prostate Specific Membrane Antigen (PSMA), Platelet Factor-4 (PF-4), and Interleukin-6 (IL-6) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Female Controls NA Serum 19775154
459 IGF1 Protein Humans Higher concentrations in patients with increased risk of prostate cancer Diagnostic NA p=0.049 NA 19491931
460 IGF1 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p<0.001 NA 19491931
461 IGFBP3 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p=0.004 NA 19491931
462 Hepatocyte Growth Factor (HGF) Protein Humans Downregulated after Polyphenon E treatment(18.9%) Predictive Before Vs After Polyphenon E treatment p<0.001 Serum 19542190
463 Vascular Endothelial Growth Factor (VEGF) Protein Humans Downregulated after Polyphenon E treatment(9.9%) Predictive Before Vs After Polyphenon E treatment p=0.032 Serum 19542190
464 Insulin Like Growth Factor (IGF-I) Protein Humans Downregulated after Polyphenon E treatment(10.4%) Predictive Before Vs After Polyphenon E treatment p=0.012 Serum 19542190
465 IGF Binding Protein-3 (IGFBP-3) Protein Humans Downregulated after Polyphenon E treatment(11%) Predictive Before Vs After Polyphenon E treatment p=0.024 Serum 19542190
466 Prostate Specific Antigen (PSA) Protein Humans Downregulated after Polyphenon E treatment(7.9%) Predictive Before Vs After Polyphenon E treatment p=0.009 Serum 19542190
467 IGF-I/IGFBP-3 Protein Humans Downregulated after Polyphenon E treatment(3.4%) Predictive Before Vs After Polyphenon E treatment p=0.028 Serum 19542190
476 GLUT1 Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p=0.005 Tissue 19854473
477 PHD1 (prolyl-4-hydroxylases 1) Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p <0.001 Cell Lines 19854473
478 Clusterin and Clusterin Density Protein Humans Upregulated: Clusterin [(BPH: 94.2 ± 38.7) Vs (PCA: 137.2 ± 36.6 )]; Clusterin Density [(BPH: 3.2 ± 2.2 ) Vs (PCA: 5.5 ± 2.6 )] Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p<0.001 Serum 19854485
479 Clusterin & Clusterin Density Protein Humans Upregulated: Clusterin [(No Metastasis 131.1 ± 32.1) Vs (Metastasis: 151.3 ± 34.6 )]; Clusterin Density [(No Metastasis: 5.1 ± 2.3 ) Vs (Metastasis: 6.2 ± 2.7 )] Prognostic No Metastasis Vs Metastasis p<0.001 Serum 19854485
480 Clusterin Density Protein Humans Upregulated: Clusterin Density [(ExtraProstatic 6.2 ± 2.4) Vs (Organ-confined disease: 5.4 ± 2.2 )]; Prognostic Organ-confined disease Vs Extraprostatic disease p=0.033 Serum 19854485
481 Clusterin Density Protein Humans Decreased expression in Patients with Biochemical Recurrence free Survival Prognostic Biochemical Recurrence Free Survival Vs No Survial p=0.034 Serum 19854485
482 PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Tumor p<0.05 Serum 20632177
483 MMP-2 Protein Humans Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58) Diagnostic Prostate Cancer Vs No Tumor p=0.038 Serum 20632177
484 PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A) Protein + DNA Humans Upregulated and Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Tumor p=0.036 Urine and Serum 20632177
492 ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated); Protein Humans Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
493 collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1; Protein Humans Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
494 transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B; Protein Humans Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
495 keratin 5; mutant desmin; histone cluster 2, H2bf; Protein Humans Downregulated ratio in Localised PCA: keratin 5 [2.08]; mutant desmin [2.03]; histone cluster 2, H2bf [2.02]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
496 e-FABP5 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Serum 19894759
497 e-FABP5 Protein Humans Upregulated in Localised PCA Diagnostic Localized PCa and BPH p<0.01 Serum 19894759
498 e-FABP5, MCCC2, PPA2, Ezrin, and SLP2 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
499 SM22 Protein Humans Downregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
515 p2PSA ([-2]isoform of proenzyme prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample p = 0.0006 Serum 20171670
516 %fPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample p=0.02 Serum 20171670
517 prostate specific antigen Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample NA Serum 20171670
518 Prostate Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample NA Serum 20171670
520 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer: (BPH Geometric Mean : 1.448 Vs Cancer Geometric Mean : 2.990) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer p=0.0001 Tissue 20392989
521 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 6): (BPH Geometric Mean : 1.448 Vs GS6 Geometric Mean : 3.452) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 6) p=0.0003 Tissue 20392989
522 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 7): (BPH Geometric Mean : 1.448 Vs GS7: Geometric Mean : 2.756) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 7) p=0.0052 Tissue 20392989
532 KLK15 (kallikrein-related peptidase) Protein Humans High levels associated with shorter progression-free survival. Prognostic PSA recurrence Vs No PSA recurrence Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 Tissue 20473923
540 MMP-9 % Protein Humans Increased expression in Recurrence free survival Prognostic Biochemical Recurrence Vs No Recurrence p=0.03 Tissue 20889560
541 MMP-9 intensity Protein Humans Increased expression in Disease Specific Mortality Prognostic Disease Specific Mortality Vs No Mortality p<0.001 Tissue 20889560
542 MMP-9 intensity Protein Humans Increased expression in Overall Mortality Prognostic Overall Mortality Vs No Mortality p<0.001 Tissue 20889560
545 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.027 Urine 20957673
549 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.027 Urine 20957673
553 Cathepsin D Protein Humans Upregulated (pmol/mL): (Controls: 4.85±1.35) Vs (Prostate Cancer: 9.2±1.75) Diagnostic Control Vs Cancer p<0.001 Serum 20973404
554 Cathepsin D Protein Humans Upregulated (pmol/mL): (BPH: 5.11±1.17) Vs (Prostate Cancer: 9.2±1.75) Diagnostic BPH Vs Cancer p<0.001 Serum 20973404
555 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
556 Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
557 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
558 Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
559 HSP60 Protein Humans Upregulated in PCa Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
560 Lamin A Protein Humans Upregulated in GS 8 and above Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
563 freePSA (free prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
564 [-2]proPSA ([-2]proenzyme prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
565 %fPSA (%free prostate specific antigen) Protein Humans Downregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
566 DKK1 (Dickkopf-1) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
567 NEM (neuroendocrine marker) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
568 Prostate Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
569 D-Dimer Protein Humans Upregulated in Progressive Disease Prognostic progressive disease (PD) Vs nonprogressive disease (non-PD) p<0.024 Blood 21088161
574 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated in PCa Diagnostic BPH vs Prostate Cancer NA Serum 21166384
575 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
576 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
577 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated Diagnostic BPH vs Prostate Cancer NA Serum 21166384
578 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
579 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
583 β-microseminoprotein (MSMB) Protein Humans increased expression with decreased biochemical recurrence-free survival Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.001 Tissue 21240253
587 Tropomyosin β chain fibroblast and epithelia, Keratin type II cytoskeletal 8 Cytokeratin 8 K, 14-3-3 protein γ protein kinase C inhibitor p, Protein disulfide isomerase precursor PDI EC 5, Keratin type I cytoskeletal 19 Cytokeratin 19, Actin muscle type A2, Desmin, α1 antitrypsin precursor, Tubulin β2 chain, 78 kDa glucose regulated protein prec GRP 78, Rho GDP dissociation inhibitor 1, Creatine kinase B chain EC 2 7 3 2 B CK, Fibrinogen γ chain precursor, Heat shock cognate 71 kDa protein, Stress 70 protein mitochondrial precursor 75 kD, Heat shock 70 kDa protein 1 HSP70 1a, Enoyl CoA hydratase mitochprecursor EC 4, Prohibitin, Apolipoprotein A I precursor Apo AI, ATP synthase β chain mitochondrial precursor, Small nuclear ribonucleoprotein 200 kDa helicas, Glycerol 3 phosphate acyltransferase EC 2 3 1 15, Keratin type I cytoskeletal 18 Cytokeratin 18, Serum albumin precursor, Annexin A4 Lipocortin IV Endonexin, Serum albumin precursor, 60 kDa heat shock protein mitochondrial precursor. Protein Humans Differentially Expressed Diagnostic BPH Vs Prostate Cancer p<0.05 Tissue 21305254
588 Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1); Protein Humans Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
589 Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
590 Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); Protein Humans Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
591 Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
592 placental growth factor (PIGF) Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
593 soluble c-kit Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
594 VEGF Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
595 sVEGFR1 Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p=0.001 Plasma 21323568
596 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Biopsy Positive Vs Biopsy Negative p<0.05 Tissue 21364037
598 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p<0.0001 Urine 21364037
599 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p<0.001 Tissue 21367627
600 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p=0.004 Tissue 21367627
601 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
602 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
603 Stromal cell-derived factor-1 (SDF-1) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
604 Stromal cell-derived factor-1 (SDF-1) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p=0.017 Tissue 21367627
605 vascular endothelial growth factor (VEGF) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p<0.001 Tissue 21367627
606 matrix metalloproteinase-9 (MMP-9) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival p<0.001 Tissue 21367627
626 fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.024 Serum 21482022
627 %fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.008 Serum 21482022
628 PSA Density Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.001 Serum 21482022
629 %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
630 Prostat Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
631 Base Model (Age+ Prostate Volume + tPSA+ fPSA) Protein Humans NA Diagnostic Prostate Cancer Vs Controls Not significant Serum 21482022
632 Base Model + %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
633 Base Model + phi Protein Humans Upregulated in PCa (phi) Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
634 NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs BPH LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS Serum 21504557
635 PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs BPH p<0.05 Serum 21504557
636 40S ribosomal protein S8; Heterogeneous nuclear ribonucleoprotein H; 78 kDa glucose-regulated protein; Cytochrome c oxidase polypeptide VIc; Cytochrome c oxidase subunit 5B, mitochondrial ATP synthase subunit beta, mitochondrial Stress-70 protein, mitochondrial Biglycan; Elongation factor Tu mitochondrial; Ubiquitin-like modifier-activating enzyme 1; Protein disulfide-isomerase A4; Heterochromatin protein 1-binding protein 3; Tumor protein D52 Prohibitin-2; Protein disulfide-isomerase; EH domain-containing protein 2; 60 kDa heat shock protein mitochondrial; Nucleophosmin Periostin; Sorbitol dehydrogenase Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
637 Desmin; Serum deprivation-response protein 3; Sorbin and SH3 domain-containing protein 1; Vimentin; Calponin-1; Heat shock protein beta-1; Actin, gamma-enteric smooth muscle; Protein kinase C delta-binding protein; Collagen alpha-1(VI) chain Laminin subunit gamma-1; Sorbin and SH3 domain-containing protein 2; Tenascin; Zyxin; Talin-1; Collagen alpha-1(I) chain; Vinculin; Mimecan; Lipoma-preferred partner; Neuroblast differentiation-associated protein AHNAK; Decorin; Basement membrane-specific heparan sulfate proteoglycan core protein; Phosphatidylethanolamine-binding protein 1 Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
638 Neuroblast differentiation-associated protein AHNAK; Glutamate dehydrogenase 1, mitochondrial; Protein disulfide-isomerase A4; Cytochrome c oxidase subunit 5B, mitochondrial; Collagen alpha-3(VI) chain; Heterogeneous nuclear ribonucleoprotein H; 10 kDa heat shock protein, mitochondrial; Elongation factor Tu, mitochondrial; 78 kDa glucose-regulated protein; Myosin-9; Protein disulfide-isomerase; Biglycan; Nucleoside diphosphate kinase B; 60 kDa heat shock protein, mitochondrial; Periostin; 60S ribosomal protein L10a Nucleophosmin; Asporin; Sorbitol dehydrogenase; Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
639 Desmin; Myosin regulatory light polypeptide 9; Serum deprivation-response protein 3; Sorbin and SH3 domain- containing protein 1; Tropomyosin alpha-1 chain; Protein kinase C delta-binding protein; Calponin-1; Vinculin; Prostatic acid phosphatase; Zyxin; Fibrinogen alpha chain; Histone H1.0; Talin-1; Protein disulfide-isomerase A3; Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
640 Periostin Protein Humans Upregulated in PCA Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.01 Tissue 21504578
641 Ki-67 Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.02; Multivariate: =0.002 Tissue 21519348
642 Norm AR (Androgen Receptor) Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.006; Multivariate: p=0.001 Tissue 21519348
643 Ki-67/lum Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men p=0.022 Tissue 21519348
653 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation p = 0.024 Serum 21520165
654 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation NA Serum 21520165
655 enhancer of zeste homologue 2 (EZH2) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p=0.004 Tissue 21592298
656 minichromosome maintenance protein 7 (MCM7) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
657 Ki-67 Protein Humans Increased expression in patients with Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
682 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (12 months) NA Serum 21741162
683 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (24 months) NA Serum 21741162
684 PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding). Protein Humans NA Prognostic Overall Survival Vs No Survival PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046. Serum 21741162
699 KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ; Protein Humans Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;] Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
700 Cofilin Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.01 Cell Lines 21820414
701 Annexin A5 Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
706 α2-macroglobulin (α2M) Protein Humans Upregulated (Healthy: 151.7±25.30 Vs without α2M deficiency: 252.45±125.07) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
707 C-reactive protein (CRP) Protein Humans Upregulated (Healthy: 109.58±89.66 Vs without α2M deficiency: 1534.6±1482.8) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
708 serum amyloid A (SAA) Protein Humans Upregulated (Healthy: 9.96±4.16 Vs without α2M deficiency: 54.7±44.5) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
709 interleukin-6 (IL-6) Protein Humans Upregulated (Healthy: 7.58±6.0 Vs without α2M deficiency: 46.50±40.65) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
710 α1 anti-chymotripsin (α1AT) Protein Humans Upregulated (Healthy: 122±28.0 Vs without α2M deficiency: 293.76±68.51) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
711 α1 acid glycoprotein (α1AG) Protein Humans Upregulated (Healthy: 67.5±25.5 Vs without α2M deficiency: 102±39.36) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
712 Ceruloplasmin (CP) Protein Humans Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.74±10.93) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
713 α2-macroglobulin (α2M) Protein Humans Downregulated with α2M deficiency (Without α2M deficiency: 252.45±125.07 Vs with α2M deficiency: 12.75±5.60) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
714 C-reactive protein (CRP) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 1534.6±1482.8 Vs with α2M deficiency: 173±90.3) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
715 serum amyloid A (SAA) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
716 interleukin-6 (IL-6) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 46.50±40.65 Vs with α2M deficiency: 3.38±2.61) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
717 α1 anti-chymotripsin (α1AT) Protein Humans Upregulated (Healthy: 122±28.0 Vs with α2M deficiency: 293.76±68.51) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
718 α1 acid glycoprotein (α1AG) Protein Humans Upregulated (Healthy: 67.5±25.5 Vs with α2M deficiency: 100.8±38.90) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
719 Ceruloplasmin (CP) Protein Humans Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.6±10.89) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
720 Katanin p60 Protein Humans Upregulated in PCa Prognostic bone metastasis (Met) Vs No bone metastasis (controls) p<0.05 Bone Marrow (Tissue) 21681775
752 CEP55 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
753 NUF2 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
754 PAGE4 Protein Humans Downregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p=0.0045 Tissue 21917134
755 CEP55 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.003) Tissue 21917134
756 NUF2 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
757 PBK Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.001) Tissue 21917134
758 TTK Protein Humans Upregulated with high Gleason Score Prognostic f For Hazrard Ratio: (p = 0.002) Tissue 21917134
759 PAGE4 Protein Humans Downregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
772 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA Diagnostic Controls Vs Patients p<0.05 Plasma 21993000
773 Catalase Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Blood 21993000
774 Superoxide Dismutase Protein Humans Upregulated in PCA Diagnostic Controls Vs Patients p<0.05 Blood 21993000
775 Vitamin -C Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Serum 21993000
776 Vitamin -E Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Serum 21993000
777 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Plasma 21993000
778 Vitamin -C Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
779 Vitamin -E Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
780 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) Plasma 21993000
781 Vitamin -C Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) Serum 21993000
782 Vitamin -E Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with no Treatment) Serum 21993000
783 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>7 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Plasma 21993000
784 Vitamin -C Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>8 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
785 Vitamin -E Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>9 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
787 Auto-antibody profile (TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes) Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic prostate cancer Vs benign disease p<0.001 Serum 22012634
788 TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Serum 22012634
789 tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
790 cPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
791 f/tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
792 c/tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
807 %p2PSA Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
808 Prostate Helth Index (phi) Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
809 %p2PSA Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
810 Prostate Helth Index (phi) Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
811 %p2PSA Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
812 Prostate Helth Index (phi) Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
817 Interleukin-18 (IL-18) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
818 Interleukin-10 (IL-10) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
819 Interleukin-18 (IL-18) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
820 Interleukin-10 (IL-10) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
827 Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1) Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
828 TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B; Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
829 Secreted frizzled-related protein (SFRP)-2 Protein Humans Downregulated in Prostate cancer (PCa: 2.28 ± 0.33 Vs Controls: 1.11 ± 0.09) Diagnostic Benign Vs malignant prostate glands p<0.0001 Tissue 22175903
830 Secreted frizzled-related protein (SFRP)-2 Protein Humans Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15) Prognostic Gleason Grade 3,4 Vs Gleason Grade 5 p<0.0001 Tissue 22175903
831 sPLA2-IIA (Secreted group IIA phospholipase A2) Protein Humans Upregulated in Prostate cancer Diagnostic Controls Vs Prostate Cancer p<0.001 Serum 22189868
832 CRP (C- Reactive Protein) Protein Humans Upregulated in Prostate cancer Diagnostic Controls Vs Prostate Cancer p<0.001 Serum 22189868
842 breast cancer antiestrogen resistance 1 (BCAR1) Protein Humans Significantly associated with Biochemical Relapse Prognostic Biochemical Recurrence p=0.02 Tissue 22241677
858 basic fibroblast growth factor (bFGF) Protein Humans Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)] Predictive ADT Treatment Vs No Treatment p=0.0006 Plasma 22302227
859 Interleukin 1 (IL-1β) Protein Humans Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)] Predictive ADT Treatment Vs No Treatment p=0.026 Plasma 22302227
860 Interleukin 8 (IL-8) Protein Humans Upregulated in Treatment Group (Treatment: 5.7 (3.8–7.7) Vs Control : 2.2 (1.6–2.8) ) Predictive ADT Treatment Vs No Treatment p=0.0001 Plasma 22302227
861 stromal cell–derived factor 1α (SDF-1α) Protein Humans Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) ) Predictive ADT Treatment Vs No Treatment p=0.023 Plasma 22302227
862 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Prostate Cancer (Healthy: 10.36±0.69 ; BPH: 9.39±0.75; PCA: 6.89±0.58) Diagnostic Healthy Controls Vs BPH VS Prostate Cancer p <0.05 Plasma 22315056
863 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Stage 2 PCa than Stage 1 PCa Prognostic Stage 1 Vs Stage 2 prostate cancer p<0.001 Plasma 22315056
864 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Patients with No survival (No Survival: 5.11±0.75 Vs Survival: 7.02±0.22) Prognostic disease specific survival Vs no survival p=0.0439 Plasma 22315056
865 Erythrocyte sphingosine kinase-1 (SphK1) Protein Humans Downregulated in PCa (Healthy: 4.7±0.42; PCa: 2.14±0.17) Diagnostic Prostate Cancer Vs Healthy Men p<0.0001 Plasma 22315056
866 Testosterone Protein Humans Downregulated in Gleason Score 8-9 Prognostic Gleason Sum 5 Vs Gleason Sum 8-9 p=0.0495 Plasma 22315056
867 Testosterone Protein Humans Upregulated in Metastases Prognostic Metastases Vs No Metastases p<0.0001 Plasma 22315056
868 Alpha2- macroglobin (α2m); Elongation Factor 1A (EFA1) ; Lumican ; Complement Factor 1 Light Chain; Heparin Cofactor 2; Inter-alpha-trypsin inhbitor heavy chain H2; Serum amyloid P-component; Histidine Rich gylcoprotien; Transthyretin Protein Humans Upregulated: [Alpha2- macroglobin (α2m) (1.4 fold); Elongation Factor 1A (EFA1) (1.2 fold); Lumican (1.1 fold); Downregulated: [Complement Factor 1 Light Chain (1.1 fold); Heparin Cofactor 2 (1.1 fold) ; Inter-alpha-trypsin inhbitor heavy chain H2 (1.1 fold) ; Serum amyloid P-component (1.1 fold); Histidine Rich gylcoprotien (1.3 fold) ; Transthyretin (1.4 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
869 Beta-2-gylcoprotien 1 + Somatomedin- B Protein Humans Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
870 Antithrombin III + Inter-alpha-trypsin inhibitor heavy chain H3 Protein Humans Downregulated: [Antithrombin III (1.4 fold)+ Inter-alpha-trypsin inhibitor heavy chain H3 (1.7 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
871 Afamin + Fibronectin 1 + Alpha-2-HS-glycoprotien chain B Protein Humans Upregulated : [Afamin (1.4 fold) + Fibronectin 1 (1.4 fold) + Alpha-2-HS-glycoprotien chain B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
872 cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228 Protein Humans Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold) Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
873 cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3 Protein Humans Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
874 Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III Protein Humans Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
875 Apliopoprotien A-IV + Complement Component 4B Protein Humans Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
876 Beta 2-Glycoprotein 1 + Somatomedin- B Protein Humans Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
877 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
878 Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin Protein Humans Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
879 Apliopoprotien A-IV + Complement Component 4B Protein Humans Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
880 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
881 cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673 Protein Humans Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
888 NK3 homeobox 1 (NKX3-1) Protein Humans Downregulated in Gleason Grade 3 Diagnostic Normal Prostate Vs Gleason Grade 3 p=0.012 Tissue 22397815
897 Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region; Protein Humans Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;) Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
898 Transthyretin (TTR) Protein Humans Downregulated (1.58 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
899 Clusterin (CLU) Protein Humans Upregulated (1.51 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
900 Transthyretin (TTR) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
901 Clusterin (CLU) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
902 (Table 1) Protein Humans Upregulated in PCa [1.12-2.25] Diagnostic Patients Vs Controls p<0.05 Serum 22499197
907 %p2PSA Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group; PCa Vs HGPIN group p<0.001 Serum 22542564
908 (percent free PSA) % fPSA Protein Humans Downregulated in PCa [No PCa: 19.36 ; PCa: 15.41; HGPIN: 22.23] Diagnostic PCa VS No PCa group; PCa Vs HGPIN group No PCa Vs PCa:p=0.004; PCa Vs HGPIN: p<0.001 Serum 22542564
909 Prostate Health Index (phi) Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group; PCa Vs HGPIN group p< 0.001 Serum 22542564
910 PCA3 Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group p< 0.001 Urine 22542564
911 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
912 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤6 Vs 7 Vs ≥8 p=0.002 Tissue 22554381
913 Ki-67 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
914 Ki-67 Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤ 6 Vs 7 Vs ≥ 8 p=0.008 Tissue 22554381
915 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.001 Tissue 22554381
916 Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.02 Tissue 22554381
917 Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.002 Tissue 22554381
929 Spondin-2 (SPON2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p=0.001 Serum 22615945
930 Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1) Protein Cell Lines Differentially Expressed in PCA Diagnostic BPH-1, LNCaP Vs C4-2 p<0.05 Serum 22615945
931 Spondin-2 (SPON2) Protein Humans Upregulated with Gleason Score >=7 and 8 Diagnostic Gleason Score (2-6), (7-8) and (9-10) p=0.001 Tissue 22615945
940 Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR) Protein Humans Downregulated in PCa [Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); ] Upregulated in PCa [Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)] Diagnostic Benign Prostatic Hyperplasia (BPH) Vs Prostate Cancer (PCa) p<0.01 Serum 22740474
961 Prostate health index (phi) Protein Humans Upregulated in PCa [No PCa: 36.84 (28.82–46.14) Vs PCa 49.97 (37.75–69.65)] Diagnostic PCa Vs No-PCa <0.001 Serum 22821756
964 Soluble interleukin-6 Receptor (sIL-6R) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.024 Serum 22866141
965 Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.011 Serum 22866141
966 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs Controls (Healthy Donors + BPH) p<0.05 Serum 22870138
967 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs BPH VS Healthy Donors p<0.05 Plasma 22870138
972 Prostate Specific Antigen (PSA) Protein Humans Downregulated with Increased BMI: [BMI <23: 9.49±3.46 Vs BMI >25: 6.28±1.36] Prognostic BMI Group <23 Vs BMI Group >25 p=0.001 Serum 22901185
973 Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa [Patients: 7.8±3; Controls: 1.9±0.98] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
974 ACP Protein Humans Upregulated in PCa [Patients: 4.8±1.8; Controls: 3.1±0.6] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
975 PAP Protein Humans Upregulated in PCa [Patients: 2.0±1.7 Controls: 0.5±0.2] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
976 RhoC score Protein Humans 10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6% Prognostic Time to PSA Failure p=0.009 Tissue 22935975
977 RhoC score Protein Humans Decreased in Cases Prognostic Time to PSA Failure p=0.009 Tissue 22935975
982 EGFR Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.01 Tissue 22977195
984 PTEN Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.02 Tissue 22977195
988 Zinc α2-glycoprotein (ZAG) Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine 23020913
989 Zinc α2-glycoprotein (ZAG) + PSA Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine + Serum 23020913
990 FLIP Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
991 Sp1 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
992 Sp3 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
993 FLIP + Sp1 + Sp3 + Gleason Score Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
1012 Survivn Protein Humans Upregulated in PCA compared to both Healthy controls and BPH Diagnostic (Normal and BPH )VS PCa p<0.001 Plasma 23091600
1013 Survivn Protein Humans Upregulated in PCA (150 pg/ml ) compared to both Healthy controls (59.7 pg/ml) and BPH (55 pg/ml) Diagnostic (Normal and BPH )VS PCa p<0.001 Serum 23091600
1014 Chromatin Assembly Factor 1 (CAF-1 p60) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Vs prostate cancer NA Tissue 23109837
1018 sICAM-1 Protein Humans Upregulated in PCa (PCa: 245.2 , Normal: 240.3) Diagnostic PCa Vs Controls p=0.005 Plasma 23171880
1019 CRP Protein Humans Upregulated in PCa (PCa: 2.5 , Normal: 2.1) Diagnostic PCa Vs Controls [Odds Ratio: p=0.03]; [Regulation: p = 0.006] Plasma 23171880
1024 Serum PSA Protein Humans NA Prognostic PCa Vs No PCA group p<0.001 Serum 23201468
1025 Serum PSA Protein Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p = 0.003 Serum 23201468
1026 Serum PSA Protein Humans NA Prognostic Tumor Stage (T3-T4) p = 0.002 Serum 23201468
1027 Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1028 PSA + Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1032 C-terminal telopeptide Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 138.16± 26.71; Risedronate: 18.24 ± 22.38) Predictive Placebo vs Risedronate (after 24 months) p =0.0014 Serum 23265571
1033 Bone-specific alkaline phosphatase Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 60.29 ± 10.28; Risedronate: 9.94 ± 6.95) Predictive Placebo vs Risedronate (after 24 months) p =0.0002 Serum 23265571
1034 N-Mid-Osteocalcin Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 100.35 ± 30.4; Risedronate: 18.85 ± 10.8) Predictive Placebo vs Risedronate (after 24 months) p =0.0173 Serum 23265571
1035 BMI1 Protein Humans Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44) Prognostic Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer p< 0.001 Serum 23308129
1036 BMI1 Protein Humans Upregulated in PCa: (Normal: 0.81 ± 0.07; PCa stage 2: 1.8 ± 0.08) Diagnostic Normal Vs PCa p< 0.05 Tissue 23308129
1037 Aminopeptidase N (APN) Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant Tissue p=0.034 Tissue 23322201
1040 Aminopeptidase N (APN) Protein Humans NA Prognostic Recurrence Free Survival Univariate: p=0.002; Mutlivariate: p=0.017 Tissue 23322201
1041 Aminopeptidase N (APN) Protein Humans NA Prognostic Cancer Specific Survival Univariate: p=0.017; Mutlivariate: p=0.049 Tissue 23322201
1043 Early Growth Response 3 (Egr3) Protein Humans Upregulated in PCa (NSR (number of strong positive pixels ratio):normal prostate: 0.039 ; NSR: prostate cancer: 0.13) Diagnostic Prostate Cancer Vs Normal Prostate p = 0.00047 Tissue 23342084
1044 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate p = 0.001 Tissue 23342084
1047 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Serum 23356551
1054 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.001 Serum 23356551
1068 AMBP precursor (AMBPf1) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.005 Urine 23417432
1069 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.004 Urine 23417432
1070 Saposin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.002 Urine 23417432
1071 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.004 Urine 23417432
1072 Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.006 Urine 23417432
1076 3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); chromosome 6 open reading frame 115 ( C6orf115 ); hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); S100 calcium binding protein P ( S100P ); dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); monoamine oxidase B ( MAOB ); thymidine phosphorylase ( TYMP ); monoamine oxidase A ( MAOA ); sequestosome 1 ( SQSTM1 ); tropomyosin 1 (alpha) ( TPM1 ); cathepsin D ( CTSD ); growth differentiation factor 15 ( GDF15 ); arginase, type II ( ARG2 ); glutaminase ( GLS ); arylacetamide deacetylase-like 1 ( AADACL1 ); aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); spermatogenesis associated, serine-rich 2-like ( SPATS2L ); N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); calpain 2, (m/II) large subunit ( CAPN2 ); acyl-CoA thioesterase 9 ( ACOT9 ); keratin 18 ( KRT18 ); epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); glutathione S-transferase kappa ( GSTK1 ); aldo-keto reductase family 1, member C2 ( AKR1C2 ); acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); mannosidase, beta A, lysosomal ( MANBA ); vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); occludin ( OCLN ); sulfide dehydrogenase like ( SQRDL ); acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); abhydrolase domain containing 11 ( ABHD11 ); acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); superoxide dismutase 2, mitochondrial ( SOD2 ); fucosidase, alpha-L- 1, tissue ( FUCA1 ); sideroflexin 3 ( SFXN3 ); carnitine palmitoyltransferase 2 ( CPT2 ); Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1077 semenogelin I ( SEMG1 ); Cyclin-dependent kinase 1 ( CDC2 ); thymidine kinase 1, soluble ( TK1 ); semenogelin II ( SEMG2 ); barrier to autointegration factor 1 ( BANF1 ); cDNA FLJ16186 ( cDNA FLJ16186 ); polo-like kinase 1 ( PLK1 ); cyclin-dependent kinase 2 ( CDK2 ); insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); stathmin 1 ( STMN1 ); ribonucleotide reductase M2 ( RRM2 ); S100 calcium binding protein A13 ( S100A13 ); GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); neural cell adhesion molecule 2 ( NCAM2 ); thyroid hormone receptor interactor 13 ( TRIP13 ); ribonucleotide reductase M1 ( RRM1 ); nucleolar pre-rRNA processing protein ( ESF1 ); stathmin-like 2 ( STMN2 ); H3 histone, family 3A ( H3F3A ); GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); H2A histone family, member Z ( H2AFZ ); DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ATPase family, AAA domain containing 2 ( ATAD2 ); SCD6 homolog B (S. cerevisiae) ( LSM14B ); chromosome 13 open reading frame 33 ( C13orf33 ); karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); acireductone dioxygenase 1 ( ADI1 ); histone cluster 1, H4a ( HIST1H4A ); lamin B1 ( LMNB1 ); 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); phosphorylase, glycogen, liver ( PYGL ); PDZ binding kinase ( PBK ); histone cluster 1, H1b ( HIST1H1B ); histone acetyltransferase 1 ( HAT1 ); Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); H2A histone family, member Y ( H2AFY ); ligase I, DNA, ATP-dependent ( LIG1 ); structural maintenance of chromosomes 4 ( SMC4 ); topoisomerase (DNA) II beta 180kDa ( TOP2B ); nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); structural maintenance of chromosomes 2 ( SMC2 ); DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); Metastasis-associated protein 1 ( MTA1 ); Protein Humans Downregulated in LNCAP-SF [semenogelin I ( SEMG1 ); ( 0.076735 fold) Cyclin-dependent kinase 1 ( CDC2 ); ( 0.081925 fold) thymidine kinase 1, soluble ( TK1 ); ( 0.083392 fold) semenogelin II ( SEMG2 ); ( 0.10883 fold) barrier to autointegration factor 1 ( BANF1 ); ( 0.17609 fold) cDNA FLJ16186 ( cDNA FLJ16186 ); ( 0.19531 fold) polo-like kinase 1 ( PLK1 ); ( 0.20362 fold) cyclin-dependent kinase 2 ( CDK2 ); ( 0.22407 fold) insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); ( 0.22637 fold) stathmin 1 ( STMN1 ); ( 0.24713 fold) ribonucleotide reductase M2 ( RRM2 ); ( 0.25054 fold) S100 calcium binding protein A13 ( S100A13 ); ( 0.2628 fold) GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); ( 0.26922 fold) neural cell adhesion molecule 2 ( NCAM2 ); ( 0.26951 fold) thyroid hormone receptor interactor 13 ( TRIP13 ); ( 0.27195 fold) ribonucleotide reductase M1 ( RRM1 ); ( 0.27289 fold) nucleolar pre-rRNA processing protein ( ESF1 ); ( 0.27757 fold) stathmin-like 2 ( STMN2 ); ( 0.28292 fold) H3 histone, family 3A ( H3F3A ); ( 0.28744 fold) GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); ( 0.28965 fold) H2A histone family, member Z ( H2AFZ ); ( 0.2989 fold) DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ( 0.3037 fold) ATPase family, AAA domain containing 2 ( ATAD2 ); ( 0.30571 fold) SCD6 homolog B (S. cerevisiae) ( LSM14B ); ( 0.30649 fold) chromosome 13 open reading frame 33 ( C13orf33 ); ( 0.3127 fold) karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); ( 0.31541 fold) Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); ( 0.32372 fold) acireductone dioxygenase 1 ( ADI1 ); ( 0.33027 fold) histone cluster 1, H4a ( HIST1H4A ); ( 0.33313 fold) lamin B1 ( LMNB1 ); ( 0.33412 fold) 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); ( 0.33637 fold) phosphorylase, glycogen, liver ( PYGL ); ( 0.33849 fold) PDZ binding kinase ( PBK ); ( 0.34986 fold) histone cluster 1, H1b ( HIST1H1B ); ( 0.35951 fold) histone acetyltransferase 1 ( HAT1 ); ( 0.36643 fold) Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); ( 0.37213 fold) nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); ( 0.37728 fold) programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); ( 0.37993 fold) H2A histone family, member Y ( H2AFY ); ( 0.38303 fold) ligase I, DNA, ATP-dependent ( LIG1 ); ( 0.38796 fold) structural maintenance of chromosomes 4 ( SMC4 ); ( 0.38871 fold) topoisomerase (DNA) II beta 180kDa ( TOP2B ); ( 0.38889 fold) nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); ( 0.39627 fold) structural maintenance of chromosomes 2 ( SMC2 ); ( 0.3968 fold) DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); ( 0.39825 fold) Metastasis-associated protein 1 ( MTA1 ); ( 0.39986 fold) ] Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1078 ACAT1 Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Diagnostic Normal Prostate Vs Bone Metastatis p = 0.0001 Tissue 23443136
1103 Apolipoprotein B Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.01 Serum 23582881
1104 Biotinidase Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.041 Serum 23582881
1105 Cell adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.046 Serum 23582881
1106 Complement factor H Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.025 Serum 23582881
1107 Ceruloplasmin Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1108 Carboxypeptidase M Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.001 Serum 23582881
1109 Intercellular adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1110 Galectin-3-binding protein Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.009 Serum 23582881
1111 Serum paraoxonase/arylesterase 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.011 Serum 23582881
1112 Poliovirus receptor-related protein 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.046 Serum 23582881
1113 Thrombospondin-1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.022 Serum 23582881
1114 Transmembrane 9 superfamily member 3 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.037 Serum 23582881
1121 Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; Protein Humans Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); Prognostic Agressive Vs Non Agressive Prostate Cancer Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); Tissue 23716368
1122 Acid ceramidase Protein Humans Downregulated in Agressive Prostate Cancer 0.18 Fold Prognostic Agressive Vs Non Agressive Prostate Cancer p = 0.04983 Tissue 23716368
1124 β-CTX (β-isomer of carboxiterminal telopeptide of collagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0049 Serum 23722472
1125 P1NP (aminoterminal propeptide of procollagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0139 Serum 23722472
1148 C-Reactive Protein (CRP) Protein Humans Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy) Prognostic Biochemical Failure Free survival p = 0.009 Serum 23818401
1149 Insulin Like Growth Factor Binding Proteins (IGFBP-3) Protein Humans Upregulated in Intervention Group Predictive Intervention Vs Control Group p = 0.002 Serum 23775525
1156 Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Diagnostic Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate p< 0.0137 Plasma 23826311
1157 Peptide ID: [7098; 8863; 9673; 10706; 24050] Protein Humans Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p< 0.0027 Plasma 23826311
1158 21PP + 5PP Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.0001 Plasma 23826311
1159 Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Prognostic Localised Vs Advanced Prostate Cancer p=0.0055 Plasma 23826311
1184 Bone Sialoprotein Protein Humans Upregulated in Bone Metastatis (BM: 38.7 ±19.3; NBM: 9.1 ± 5.8) Prognostic Bone Metastatis Vs No Bone Metastatis p<0.05 Tissue 23904377
1198 Angiogenin Protein Humans Upregulated in Patients with PCa (median): [Cancer 487,500 vs. Non Cancer: 414,800) Diagnostic Prostate Cancer Vs Non Cancer p = 0.008 Serum 23921786
1206 Neuropeptide‐Y (NPY) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1207 Neuropeptide‐Y (NPY) + Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1211 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; BPH: 0.47 ± 0.02) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Tissue 24063616
1212 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; NP: 1.22 ± 0.15) Diagnostic Prostate Cancer Vs Normal Prostate p= 0.0001 Tissue 24063616
1217 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1221 β-Microseminoprotein Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions p = 0.01 Urine 24115268
1222 β-Microseminoprotein + PSA Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions β-Microseminoprotein: [p = 0.01] Urine 24115268
1223 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulted in Lethal PCa Prognostic Lethal Vs Non Lethal Prostate Cancer p< 0.01 Tissue 24130224
1232 N-terminal propeptide of collagen type I (PINP) Protein Humans Upregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastatis P < 0.001 Serum 24179387
1233 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 24183365
1234 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer VS HGPIN p<0.05 Tissue 24183365
1235 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 6 Vs Gleason Score 8 p<0.05 Tissue 24183365
1236 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 7 Vs Gleason Score 8 p<0.05 Tissue 24183365
1237 Peroxisome proliferator activated receptors (PPAR) [PPARβ/δ] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1238 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1239 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Prognostic Low Vs Moderate Vs High Gleason Score p<0.05 Tissue 24189640
1242 iXip: [IgM] + [tPSA] Protein Humans Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098] Diagnostic Prostate Cancer Vs Controls p <0.001 Serum 24240583
1243 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Tissue p<0.0001 Tissue 24240687
1244 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Tumor Stage Prognostic Tumor Stage pT2 Vs pT3 Vs pT4 p= 0.004 Tissue 24240687
1245 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Gleason Score Prognostic Gleason Score 3 Vs 4 Vs 5 p=0.028 Tissue 24240687
1246 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Increased in Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p = 0.0038; Multivariate: p =0.036 Tissue 24240687
1247 Anterior gradient 2 [AGR2] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.026 Urine 24251762
1248 Thrombospondin-1 [TSP-1] Protein Humans Increased levels indicate better overall survival in Tasquinimod arm Predictive Overall Survival in Tasquinimod Vs Overall Survival in Placebo arm p=0.034 Plasma 24255071
1249 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p < 0.001; Multivariate: p =0.023 Blood 24255071
1250 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p = 0.006 Blood 24255071
1251 Active Hepatocyte Growth Factor [aHGF] Protein Humans Upregulated in PCa: [Controls: 111.3; Localised PCa: 235.2] Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.003 Urine 24266816
1252 Insulin Like Growth Factor Binding Protein 3 (IGFBP3) Protein Humans Upregulated in PCa: [Controls: 0.648; Localised PCa: 0.8862] Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.003 Urine 24266816
1253 Osteopontin (OPN) Protein Humans Upregulated in PCa: [Localised PCa: 613.6; Metastaic PCa: 1024] Prognostic Localised Vs Metastatic Prostate Cancer p = 0.003 Urine 24266816
1266 Claudin 1 Protein Humans Downregulated in LNCaP (9.3 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p = 0.04 Cell Lines 24358122
1267 Claudin 7 Protein Humans Downregulated in LNCaP (1.1 fold); DU145 (1.1 fold); PC-3 (1.5 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p < 0.01 Cell Lines 24358122
1268 Claudin 7 Protein Humans Downregulated in CAHPV-10 Prognostic CAHPV-10 Vs PC-3 p < 0.01 Cell Lines 24358122
1269 α-catenin Protein Humans Downregulated in LNCaP (4.4 fold); DU145 (2 fold); Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 LNCaP: p = 0.03; DU145: p=0.04 Cell Lines 24358122
1270 E-cadherin Protein Humans Downregulated in CAHPV-10 (1.7 fold); DU145 (1.5 fold); Upregulated in LNCaP: (2.7 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p < 0.01 Cell Lines 24358122
1271 ITGA3; ITGB1; TLN1; VCL; ITGA1; FLNC; Protein Humans Differentially Expressed Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24371517
1272 Integrin α3 [ITGA3] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.005 Urine 24371517
1273 Integrin β1 [ITGB1] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.01 Urine 24371517
1274 BTF3 Protein Humans Upregulated in PCa (2.5 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1275 HINT1 Protein Humans Upregulated in PCa (2.3 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1276 NDRG1 Protein Humans Upregulated in PCa (2.6 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1277 ODC1 Protein Humans Upregulated in PCa (1.8 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1278 BTF3 + HINT1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1279 BTF3 + NDRG1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1280 BTF3 + ODC1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; ODC1: 1.8 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1281 HINT1 + NDRG1 Protein Humans Upregulated in PCa [NDRG1: 2.6 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1282 HINT1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1283 NDRG1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1284 PDCD6IP; EEF1A2; FASN; VPS28; PABPC1;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; YWHAE; SLC3A2; ARF1; CXADR; EHD4; HSP90AB2P; HSP90AB3P; IQGAP1; KRT9; KRT2; MFGE8; PARK7; PGK1; PRDX1; RAB10; RAB1A;RAP1A; AHCY; TUBA1A; CCT5; UGDH; Protein Humans Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): [] Diagnostic PC346C vs PNT2C2 p<0.05 Cell Lines 24391718
1285 PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; CD9; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6 ;F11R; ATP12A; CTNNB1; ENO1;KPNB1; PKM2; TPI1; YWHAE; SLC3A2; EHD4; PTGFRN; HSP90AB2P; HBB; KRT9; KRT2; MFGE8; PARK7; RAB1A; RAC1; AHCY; CCT5; Protein Humans Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): [] Diagnostic PC346C vs RWPE p<0.05 Cell Lines 24391718
1286 PDCD6IP; UBA52; BCAM; PABPC1; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; ARF1; CD151; CXADR; HSP90AB3P; IQGAP1; PGK1; PRDX1; RAB10; RAP1A; TUBA1A; UGDH; Protein Humans Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): [] Diagnostic VCaP vs PNT2C2 p<0.05 Cell Lines 24391718
1287 PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; BCAM; CD9;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; HSPA5; YWHAQ; CD151; PTGFRN; HBB; RAC1; Protein Humans Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): [] Diagnostic VCaP vs RWPE p<0.05 Cell Lines 24391718
1325 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic PCa Specific Mortality Vs No Mortality p<0.001 Tissue 24486077
1326 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic Progression Vs No Progression p<0.001 Tissue 24486077
1327 Human Serum Albumin Complexed with Myristate and Aspirin; Apolipoprotein-D; Prostaglandin H2 D-isomerase; Ig A1 Bur; G-protein coupled receptor 115; Cadherin-1; α-N-acetylglucosaminidase; Pro-epidermal growth factor; Apolipoprotein-J precursor; Human Beta-Defensin-1; Matrilin-4; CD14 antigen; Chemo- kine-like factor superfamily-5 isoform a; Fibronectin precursor; Immunoglobulin-kappa light chain varia- ble region; SLURP1. Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1328 Cadherin -1 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1329 Fibronectin Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1330 TP53INP2 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1344 Bone Alkaline Phosphatase [BAP] Protein Humans Upregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1345 C-terminal of type 1 collagen [CICP] Protein Humans Downregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1346 Pyridinoline [PYD] Protein Humans Downregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1347 Bone Alkaline Phosphatase [BAP] Protein Humans NA Prognostic Overall Survival Vs No Survival p<0.001 Serum 24565955
1348 C-terminal of type 1 collagen [CICP] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1349 Pyridinoline [PYD] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1350 N-telopeptides of type 1 collagen [NTx] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1352 ERG Protein Humans NA Prognostic Histopathological Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1353 ERG Protein Humans NA Prognostic Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1371 CCND1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.042 Tissue 24708576
1372 HMMR Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.005 Multivariate; p=0.008 Tissue 24708576
1373 HOXC6 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.05 Tissue 24708576
1374 IGF1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.039 Multivariate; p=0.015 Tissue 24708576
1375 MAP4K4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.024 Tissue 24708576
1376 MKI67 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.026 Tissue 24708576
1377 SIAH2 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.016 Tissue 24708576
1378 SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.01 Multivariate; p=0.016 Tissue 24708576
1379 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (3 years) p=0.052 Tissue 24708576
1380 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (5 years) p=0.024 Tissue 24708576
1414 POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; Protein Humans Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] Prognostic Agressive Vs Non Agressive PCa NA Tissue 24741114
1415 TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; Protein Humans Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] Prognostic Metastatic Vs Non Metastatic Prostate Cancer NA Tissue 24741114
1416 ATRN; CATD; BTD; MTA1; NCAM1; PECA1; Protein Humans Upregulated in PCa: [];Downregulated in PCa: [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24741114
1417 NAAA Protein Humans Downregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1418 PTK7 Protein Humans Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.01 Tissue 24741114
1419 NAAA+ PTK7 Protein Humans NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1420 Macrophage Colony Stimulating Factor (M-CSF) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1421 CC chemokine ligand 18 (CCL-18) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1422 Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1423 Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6] Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1428 DAB2IP Protein Humans Reduced in lower FFBF (Freedom From Biochemical Faliure) Prognostic Freedom From Biochemical Failure Vs Biochemical Failure p=0.04 Tissue 24867541
1440 MUC1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Tissue 24909936
1441 p53 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.005 Tissue 24909936
1442 AZGP1 Protein Humans Increased with Decreased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.04 Tissue 24909936
1443 MUC1 + p53+ AZGP1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality NA Tissue 24909936
1453 Glutathione (GSH) Protein Humans Downregulated after treatment with SeMet for 9 months (0.22 ± 0.07 change from baseline) Predictive Baseline Vs 9 months later after treatment with SeMet p<0.05 Blood 24938534
1454 Prostate Health Index (phi) Protein Humans Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)] Diagnostic Negative Vs PCa (Segregated on the basis of Prostate Volume) Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009 Serum 24978824
1455 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Gleason Score p< 0.001 Serum 24992524
1456 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Prostate Cancer Stage p = 0.007 Serum 24992524
1457 Brachyury Protein Humans Increases with increasing Gleason Score Prognostic Gleason Score GS <7 Vs GS = 7 Vs GS >7 p = 0.027 Tissue 25009296
1458 Vascular Endothelial Growth Factor (VEGF) Protein Humans Upregulated in PCa (PCa: 356.3±181.1; BPH: 147.5±80; Healthy: 124.9±50.8) Diagnostic Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals) p<0.001 Serum 25032132
1459 Vascular Endothelial Growth Factor (VEGF) + Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa: [VEGF+ PSA] Diagnostic Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals) NA Serum 25032132
1460 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.002 Tissue 25057439
1461 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.001 Tissue 25057439
1462 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T4 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.004 Tissue 25057439
1463 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Stage T3-T5 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.009 Tissue 25057439
1464 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T6 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.007 Tissue 25057439
1465 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.013 Tissue 25057439
1466 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.019 Tissue 25057439
1467 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.026 Tissue 25057439
1468 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Increased Coexpression in patients with Decreased overall Survival Prognostic Overall Suvival Vs No Survival p=0.047 Tissue 25057439
1472 PTEN Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0011 Tissue 25075204
1473 CCND1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.036 Tissue 25075204
1474 SMAD4 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0035 Tissue 25075204
1475 PTEN + CCND1 +SMAD4 + SSP1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.00000456 Tissue 25075204
1476 pS6 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.021 Tissue 25075204
1477 pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.019 Tissue 25075204
1478 CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.000013 Tissue 25075204
1489 Interleukin-1β (IL-1β) Protein Humans Increased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.02 Tissue 25075566
1490 Interferon β (IFNβ) Protein Humans Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.008 Tissue 25075566
1491 Interleukin-1β (IL-1β) + Interferon β (IFNβ) Protein Humans Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.004 Tissue 25075566
1501 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1502 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1503 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1504 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1505 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1506 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1507 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1508 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1509 Base model (Age and total PSA) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Plasma 25151013
1510 Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Plasma 25151013
1511 Prostate Health Index (PHI) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Plasma 25151013
1512 Base model (Age and total PSA) Protein Humans NA Diagnostic High-grade Prostate cancer NA Plasma 25151013
1513 Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]) Protein Humans NA Diagnostic High-grade Prostate cancer p<0.0001 Plasma 25151013
1514 Prostate Health Index (PHI) Protein Humans NA Diagnostic High-grade Prostate cancer p<0.0001 Plasma 25151013
1515 YWHAZ Protein Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8 p<0.001 Tissue 25156059
1516 YWHAZ Protein Humans Increased expression in patients with PCa specific death Prognostic High Risk vs Low Risk (Survival) Univariate: p=0.004; Multivariate: p = 0.015 Tissue 25156059
1517 YWHAZ Protein Humans Increased expression in patients with Castration Resistant Prostate Cancer (CRPC) Prognostic Castration Resistant Prostate Cancer (CRPC) Vs No CRPC Univariate: p=0.005; Multivariate: p = 0.008 Tissue 25156059
1518 YWHAZ Protein Humans Increased expression in patients with PSA Relapse Prognostic High Risk vs. Low Risk (Relapse Univariate: p=0.005; Multivariate: p = 0.019 Tissue 25156059
1519 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated 4K Score in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer PSA >3ng/ml: p<0.01; All Patients: p<0.04 Serum 25168616
1520 PCA3 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer PSA >3ng/ml: p=0.01; All Patients: p<0.01 Serum 25168616
1521 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]+ PCA3 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer NA Serum 25168616
1523 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Gleason Score 6-7 Vs Gleason Score 8-9-10 univariate: p=0.0011; Multivariate: 0.0038 Tissue 25170626
1524 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Stage pT2 Vs Stage pT3 univariate: p=0.0099; Multivariate: 0.0104 Tissue 25170626
1525 Yin Yang 1 (YY1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1526 Death Receptor 5 Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1527 Yin Yang 1 (YY1) Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1528 Death Receptor 5 Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1529 8-hydroxydeoxyguanosine (8-OHDG) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p<0.0001 Tissue 25175169
1530 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.015 Tissue 25175169
1531 Nuclear-nuclear factor erythroid 2-related factor 2 (n-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.016 Tissue 25175169
1532 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Biochemical Failure Free Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1533 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Overall Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1536 E Cadherin Protein Humans Downregulated in patients with early relapse Prognostic Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT) p=0.02 Tissue 25227682
1537 Ki-67 Protein Humans Upregulated in patients with early relapse Prognostic Early Relapse Vs No Relapse EBRT cohort: p=0.0006; PADT Cohort: p=0.0004 Tissue 25227682
1538 C-Terminal Fragment of PSA Protein Humans Upregulated in PCa (PCa: 117; Non PCa: 36.8) Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.0016 Urine 25233230
1547 STEAP2 (Six transmembrane epithelial antigen of the prostate) Protein Humans Upregulated in DU145 and PC3 (28 fold) Diagnostic Cancerous Vs Non Cancerous Cell Lines p<0.001 Cell Lines 25248617
1556 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p<0.0001 Tissue 9815775
1557 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0001 Tissue 9815775
1558 Versican Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0006 Tissue 9563891
1559 Decorin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0078 Tissue 9563891
1560 Versican Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0003 Tissue 9563891
1562 WISP1 Protein Humans Increased with decreased BCR survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: p = 0.028;Cohort 3: p= 0.042 Tissue 31069142
1563 WISP1 Protein Humans Upregulated with increasing Stage Prognostic pTNM 2 Vs pTNM 3 Vs pTNM 4 p<0.05 Tissue 31069142
1571 Osteopontin (OPN) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.036 Tissue 31059955
1572 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.001 Tissue 31059955
1573 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased DMFS Prognostic Distant Metastasis Free Survival Vs Distant Metastasis Free Survival p = 0.045 Tissue 31059955
1582 Ki-67 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p<0.0001 Tissue 25294917
1583 Cox-2 Protein Humans Upregulation Prognostic Distant Metastatis Vs No Distant Metastatis p=0.04 Tissue 25294917
1584 p16 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.0065 Tissue 25294917
1585 MDM2 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.036 Tissue 25294917
1591 uPA/PAI-1 Protein Humans Upregulated in PCa (PCa: 0.0479 ± 0.0060; BPH: (0.0332 ± 0.0023) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.0064 Tissue 25323935
1594 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated in GS ≤ 7 Prognostic Gleason Score <7 and Gleason Score ≤7 p<0.0001 Blood 25454615
1595 Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa [BPH: 7.2 (1.8-19.8); PCa: 7.7 (1.0-19.4)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p = 0.0407 Serum 26254378
1596 %fPSA Protein Humans Downregulated in PCa [BPH: 16.7 (1.8-45.4); PCa:11.7 (4.1-31.7)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.0001 Serum 26254378
1597 Prostate Health Index (phi) Protein Humans Upregulated in PCa [BPH: 35.1 (13.1-155.6); PCa:61.6 (17.0-231.8)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.0001 Serum 26254378
1598 −2proPSA Protein Humans Upregulated in PCa [BPH: 16.0 (3.0-81.0); PCa: 21.0 (4.0-135.0)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p = 0.0004 Serum 26254378
1602 Vascular endothelial growth factor A (VEGF-A) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Tissue 26268996
1603 Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Tissue 26268996
1665 PLZF (Promyelocytic leukemia zinc finger protein) Protein Humans High expression associated with shorter disease-free survival time Diagnostic Normal Vs Primary and Metastatic PCa NA Tissue 25807461
1666 tPSA Protein Humans Upregulated in PCa Cell Lines Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1667 %fPSA Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1668 p2PSA Protein Humans Downregulated in Primary and Metastatic PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1669 %p2PSA Protein Humans Upregulated in PCa (PCa: 6.7; No PCa: 6.01) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1670 PHI (Prostate Health Index) Protein Humans Downregulated in PCa (PCa in %: 13.5; No PCa in %: 17.6) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1671 tPSA + fPSA Protein Humans Upregulated in PCa (PCa: 14.92; No PCa: 11.79) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1672 tPSA + %fPSA Protein Humans Downregulated in PCa (PCa in %: 20.5 ; No PCa in %: 15.5) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1673 fPSA + p2PSA Protein Humans Upregulated in PCa (PCa: 48.62; No PCa: 33.35) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1674 %fPSA + %p2PSA Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1675 PSA + %fPSA + %p2PSA Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1676 tPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1677 fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1678 p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1679 %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1680 %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1681 PHI Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1682 tPSA+ fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1683 tPSA+ %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1684 fPSA + p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1685 %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1686 PSA + %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1687 TIMP1 (Tissue Inhibitor Of Metalloproteinase 1) Protein Humans NA Diagnostic PCa Vs No PCa p=0.003 Serum 25967040
1688 sE-Cadherin Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1689 Clusterin Protein Humans NA Diagnostic PCa Vs No PCa p=0.004 Serum 25967040
1690 MMP9 Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1691 Galectin Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p=0.01 Serum 25967040
1692 sE-Cadherin Protein Humans Upregulated in PCa Prognostic Gleason Pattern 3 Vs 4 Vs 5 p=0.02 Serum 25967040
1693 sE-Cadherin Protein Humans Downregulated in PCa Prognostic Gleason Upgrade Vs No Gleason Upgrade p=0.03 Serum 25967040
1711 ERG Protein Humans Upregulated in PCa (Tissue, Serum) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 26172920
1712 SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.004 Tissue 26172920
1713 ERG; SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.003 Tissue 26172920
1720 FOXM1 (Forkhead Box M1) Protein Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Tissue 30719174
1721 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Low & Intermediate Risk Vs High Risk p<0.001 Tissue 30719174
1722 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.022; Multivariate: p=0.035 Tissue 30719174
1723 Zn/PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.0001 Serum 30672309
1753 5-hmC (5-hydroxymethylcytosin)+ ERG negative Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.01; Multivariate: p=0.003 Tissue 30818754
1754 AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML Protein Humans NA Prognostic Biochemical Relapse Vs No Biochemical Relapse AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03 Tissue 30288742
1755 AZGP1; Ki67; PML Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04 Tissue 30288742
1756 AZGP1 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death p=0.002 Tissue 30288742
1757 AZGP1+Ki67 Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse Discovery: Univariate: p=0.03; Multivariate: p=0.04 Tissue 30288742
1758 AZGP1+Ki67 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05 Tissue 30288742
1761 CGA (chromogranin A) Protein Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0416 Serum 30286478
1809 AMACR (Alpha methylacyl A coenzyme racemase) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Semen 30337219
1810 AMACR (Alpha methylacyl A coenzyme racemase) + Age Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Semen 30337219
1811 PHI (Prostate Health Index) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1812 PHID (Prostate Health Index Density) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1821 AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia p<0.05 Urine 30610587
1858 PDGF-BB (Platelet Derived Growth Factor-BB) Protein Humans Upregulated in Recurrent PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.04 Urine 30374275
1859 PDGF-BB/Cr (Platelet Derived Growth Factor-BB/creatinine) Protein Humans Upregulated in Recurrent PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.016 Urine 30374275
1875 KNG1 (Kininogen-1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p<0.05 Urine 30237853
1879 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.037 Serum 30446464
1880 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0028 Serum 30446464
1881 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Overall Survival Vs No Overall Survival p=0.043 Serum 30446464
1882 Keratin, type II cytoskeletal 2 epidermal; Serum amyloid P‐component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin D‐binding protein; Ig kappa chain V‐II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4; Ig alpha‐1 chain C region; Afamin; Protein Humans Increased in Progression Free survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1883 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Progression Free Survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1884 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Overall Survival Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1885 SCO‐spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid P‐component; g heavy chain V‐I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2; Protein Humans Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid P‐component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin D‐binding protein (2.4 fold); Ig kappa chain V‐II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4 (1.8 fold) ; Ig alpha‐1 chain C region (1.7 fold) ; Afamin (1.5 fold); Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1886 Isoform 2 of Eukaryotic translation initiation factor 2‐alpha kinase 4; Keratin type I cytoskeletal 10; SCO‐ spondin; Serum amyloid P‐component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain V‐IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; Protein Humans Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein A‐I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4 (0.2 fold); Inter‐alpha‐trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain V‐III region BRO (0.2 fold); Ig gamma‐2 chain C region (0.2 fold); Ig gamma‐3 chain C region (0.2 fold);] Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1887 Ig heavy chain V‐III region BRO; Alpha‐1‐antitrypsin; Plasminogen (0.1‐ fold); Ig heavy chain V‐III region TIL, Hemopexin; Afamin; Inter‐alpha‐trypsin inhibitor heavy chain H1; Protein AMBP; Alpha‐1B‐glycoprotein; Complement component C8 alpha chain; Protein Humans Upregulated in PCa [Alpha‐1‐acid glycoprotein 1 (13.6‐fold); Alpha‐1B‐glycoprotein (11.6‐fold); von Willebrand factor (5.0‐fold); Ig heavy chain V‐II region NEWM (6.0‐fold); Ig heavy chain V‐III region BRO (5.7‐fold); Afamin (5.4‐fold); Apolipoprotein A‐I (4.9‐fold); Isoform 3 of Vitamin D‐binding protein (4.3‐fold); Complement C1r subcomponent (4.3‐ fold); Angiotensinogen (4.1‐fold); Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1910 HSP27; prohibitin; GSTP1; fibrinogen β chain; ALDH6A1; A1AT; HSP60; Protein Humans Downregulated in Metastatic PCa Diagnostic Metastatic Prostate Cancer Vs No Prostate Cancer NA Tissue 30396985
1911 HSP27 Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p=0.007 Tissue 30396985
1912 Prohibitin Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1913 ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1914 Prohibitin+ HSP27+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1915 Prohibitin+ HSP27 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1916 Prohibitin+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1917 CAV1; TP53; MAGEA11; CALM1; EGFR; UBE2I; CALR; SMAD3; FHL2; HDAC1; APP; MYC; JUN; ESR1; GNB2L1; HIPK3; SMAD2; APPBP2; CDC2; BRCA1; RB1; SMAD1;PXN; XRCC6; IL6ST; STAT3; DLG1; AES; TRAF6; FLNA; TRIM29; PCAF; REPS2; AKT1; PRKCA; RAF1; HLA-B; TRAF2; SMARCA4; MAPK1; CHGB; RANBP9; CCND1; GSK3B; HSPA1A; BCL2; VCL; RAI17; TGFBR1; SELENBP1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 22654636
1918 CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Prostate Cancer Vs Lymph Node Metastasis NA Tissue 22654636